Calcifediol
Rayaldee (calcifediol) is a small molecule pharmaceutical. Calcifediol was first approved as Calderol on 1982-01-01. It is known to target vitamin D 25-hydroxylase.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Rayaldee (discontinued: Calderol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcifediol
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RAYALDEE | Eirgen Pharma | N-208010 RX | 2016-06-17 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
rayaldee | New Drug Application | 2020-12-07 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Calcifediol, Rayaldee, Eirgen | |||
9861644 | 2034-03-14 | DP | |
10300078 | 2034-03-14 | DP | |
10357502 | 2034-03-14 | DP | |
11253528 | 2034-03-14 | DP | |
8426391 | 2028-08-27 | U-1872 | |
8361488 | 2028-07-19 | DP | |
8207149 | 2028-04-25 | U-1871 | |
8778373 | 2028-04-25 | U-1873 | |
9408858 | 2028-04-25 | U-1888 | |
9498486 | 2028-04-25 | U-1920 | |
9925147 | 2028-04-25 | DP | U-2255, U-2256, U-2257, U-2258, U-2259 |
11154509 | 2028-04-25 | U-3248 | |
8906410 | 2027-02-02 | DP | |
9943530 | 2027-02-02 | U-2274 | |
10213442 | 2027-02-02 | DP |
ATC Codes
A: Alimentary tract and metabolism drugs
— A11: Vitamins
— A11C: Vitamin a and d, incl. combinations of the two
— A11CC: Vitamin d and analogues
— A11CC06: Calcifediol
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H05: Calcium homeostasis
— H05B: Anti-parathyroid agents
— H05BX: Other anti-parathyroid agents in atc
— H05BX05: Calcifediol
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | 1 | 3 | 2 | 7 |
Chronic renal insufficiency | D051436 | N18 | — | 1 | — | 1 | 1 | 3 | |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Autism spectrum disorder | D000067877 | F84.0 | — | 1 | 2 | — | — | 3 | |
Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 1 | 1 | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
Drug resistant epilepsy | D000069279 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | CALCIFEDIOL |
INN | calcifediol |
Description | Calcidiol is a hydroxycalciol that is calciol in which the hydrogen at position 25 has been replaced by a hydroxy group. A prehormone resulting from the oxidation of calciol in the liver, it is further hydroxylated in the kidney to give calcitriol, the active form of vitamin D3. It has a role as a bone density conservation agent, a nutraceutical, a metabolite, a human metabolite and a mouse metabolite. It is a hydroxycalciol, a member of D3 vitamins and a diol. |
Classification | Small molecule |
Drug class | vitamin D analogs |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O.O |
Identifiers
PDB | — |
CAS-ID | 19356-17-3 |
RxCUI | 1855064 |
ChEMBL ID | CHEMBL3544909 |
ChEBI ID | — |
PubChem CID | 5283731 |
DrugBank | DB00146 |
UNII ID | T0WXW8F54E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CYP2R1
CYP2R1
Variants
Clinical Variant
No data
Financial
Rayaldee - Opko Health
$
€
£
₣

Mock data
Subscribe for the real data
Subscribe for the real data

Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,134 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
2,045 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more